Kestrel Therapeutics secured FDA clearance for an IND to begin a first‑in‑human Phase I trial of KST‑6051, an oral pan‑KRAS inhibitor targeting KRAS‑driven cancers. The company plans to initiate the FALCON study by the end of the first quarter and will evaluate safety, pharmacokinetics and early signs of antitumor activity. The IND marks another entrant into the KRAS inhibitor space as companies pursue strategies beyond allele‑specific G12C agents. An oral pan‑KRAS small molecule could broaden applicability across KRAS mutant tumors if safety and target engagement are confirmed in early cohorts.